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Received 15 September 1983 
High concentrations of a newly-identified biologically potent peptide, neuropeptide Y, have been 
demonstrated in 3 related mouse neuroblastoma-derived donal cell lines, N18TG2 0.35 pmol/mg protein, 
NGlOS-15 0.44 pmol/mg protein and NCB-20 0.39 pmol/mg protein. The NG108-15 cell line was chosen 
for further evaluation. Dexametbasone (10&M) and nerve growth factor (10 ng/ml) resulted in a 2-fold 
increase in cellular neuropeptide Y concentrations. The response to dexamethasone was demonstrated to 
be dose-dependent. Exposure to both agents in combination resulted in a more than additive effect, 
indicating synergism. 
1 m INTRODUCTION 
CuIture of NGlOS-15 ne~robl~stoma x glioma 
somatic hybrid cells has allowed the investigation 
of differentiated neuronal function at a molecular 
level. The NG108-15 cell line possesses many 
neuronal properties including eIectricaI excitability 
[lt2] mediated by activation of specific sodium 
charmels f3] and the ability to form synapses in 
vitro [ 1,2,4]. These cells synthesize the 
neurotransmitter acetylcholine which is rekeased in 
response to stimulation [5]. The cells were derived 
by hybridization of the N18TG2 mouse 
neuroblastoma with the C6BU-1 rat gIioma clone. 
Recently it has become apparent hat some or aII 
neurones may not only possess a ‘classical’ 
neurotransmitter, but also a neuropeptide which 
may also fulfill a neurotransmitter ole. This has 
led to the concept of ‘co-localisation’ of 
* To whom correspondence should be addressed 
neurotransmitters [a]. Although the control of 
acetylcholine synthesis and release has been in- 
vestigated extensively, little attention has been 
directed towards the possible peptidergic nature of 
cultured neuroblastoma cells, although they have 
been reported to contain enkephalins [7]. We have 
examined a number of neurobIastoma and 
neuroblastoma hybrid cell lines (incfuding 
NGlO8-15) and have i~v~tigated the presence of a 
novel peptide in these cells. Neuropeptide Y (NPY) 
is a 36 amino acid peptide characterized by N- 
terminal tyrosine and C-terminal tyrosine amide 
residues [8,9]. Since its isolation from porcine 
brain, it has been demonstrated in abundance 
within neurones both in the central [lo] and 
peripheral [I 1) nervous systems. It has been iden- 
tified within the adrenal medulla [12] and in 
ganglioneuroblastomas [ 131. The possibility that 
NPY might be synthesized in vitro by one or more 
estabiished celf lines would allow experimental in- 
vestigation under controlled conditions to examine 
the reguIation of its synthesis and release. 
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Fig. 1. Results show the changes in intracellular NPY-LI 
concentration of cultured NGIOS-15 cells in the absence 
or presence of dexamethasone (lOpM), nerve growth 
factor (IO ngfml) or both, The ceRs were harvested at 
the times shown from 3 replicate dishes. Data points 
show means + SD. 
the cells with dexamcthaso~e (GOVE} or NGF 
(10 ng/ml) alone. The mean concentration of 
NPY-LI in cells incubated in medium containing 
both NGF and dexamethasone for a period of 6 
days was 11.9 it 2.35 pmol/mg protein. In cells 
cultured without these additions, the concen~atiun 
was 1. S k 0.7 pmol/mg protein, Cells incubated in 
dexamethasone alone contained a maximum NPY 
level of 2.75 f 0.53 pmolfmg protein and those in- 
cubated with NGF a level of 3.39 zt 0.96 pmol/mg 
protein (fig.1). Culture in the presence of either 
agent alone was accompanied by a a-fold increase 
in ceil content of NPY-LI, whereas the response 
seen in cehs exposed to both agents represents an 
s-fold increase in NPY-LI cell content. 
In all cases the maximum response was seen 
after 6 days incubation with a subsequent decline 
in the concentration of NPY-LI (not shown). 
NGlW15 cells were also incubated with selected 
concentrations of dexamethasone between 1 nM 
and 1OpM for a period of 6 days (fig.2). Results 
~ex~rneth~s~ne concn i M 1 
Fig.2. Results show the increase in celhdar NPY-LI 
concentration that accompanies culture of NGIOS-15 
cells for 6 days in the absence or presence of 
dexamethasone at concentrations between 1 nM and 
10/~M. Error bars show SD of triplicate results. 
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Fig.3. HPLC profiles of porcine NPY standard, and 
extracts of NGIOS-15 cells. Details of procedure are 
given in section 2. 
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of this indicate a maximum response between 10 
and 100 nM which is sustained at higher 
concentrations. 
HPLC chromatographic analysis of cell extracts 
showed that the NPY-LI co-eluted in the position 
of the porcine NPY standard at 45% acetonitrile 
(fig.3). Recovery from the columns exceeded 85% 
in all cases. 
4. DISCUSSION 
Cells of the neuroblastoma or neuronal somatic 
hybrid clones have been shown to contain high 
concentrations of NPY-LI. Although only recently 
discovered, this mammalian europeptide has been 
identified in numerous anatomical sites, but is con- 
fined to cells derived from the neural crest. Its role 
within the central nervous system remains obscure, 
but peripherally NPY possesses potent 
v~~onstrictor properties [ l&16]. NPY is located 
in noradrenergic neurones [ 17,181, and electrical 
field stimulation of mouse vas deferens has sug- 
gested that NPY, in common with the enkephalins, 
may modulate noradren~i~e release [19]. It is of 
interest therefore to have identified high concen- 
trations of NPY in a cholinergic cell line 
(NG108-15). This is the first report of NPY 
localization in cells expressing features of differen- 
tiated cholinergic nerves. 
The cellular concentrations of NPY were found 
to be increased on exposure of the NG108-15 cells 
to dexameth~one or nerve growth factor. In these 
experiments cell division had been arrested by 
culture for 24 h in cytosine arabinoside. In many 
neuroblastoma and hybrid cell lines, cellular dif- 
ferentiation may be initiated by NGF, elevation of 
cyclic-AMP or other stimuli. The expression of 
more highly differentiated neuronal functions in 
the cultured cells, e.g., synapse formation with ad- 
dition of dibutyryl cyclic AMP to NGlOS-15 cells 
[2], is accompanied by a significant reduction in 
the rate of cell division. To eliminate from these 
experiments the non-specific effects of arrested cell 
division on the synthesis of NPY, all manipula- 
tions were performed on a population of non- 
dividing cells. Over 6 days, both agents resulted in 
a doubling of NPY concentration. Both agents had 
profound morphologic~ effects upon these cells; 
in particular nerve growth factor accelerated the 
formation of neurite outgrowths. Continued ex- 
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posure of the cells to dexamethasone and nerve 
growth factor resulted in an increase in NPY con- 
centrations that was more than additive indicating 
synergism between these two agents. 
The changes in cellular concentration of NPY 
appear to accompany the increased neuronal dif- 
ferentiation in these cells. Dexamethasone alone 
has been shown to increase concentrations of the 
two opiate peptides; methionine- and leucine- 
enkephalin [20]. In contrast to this study the 
response was rapid, occurring within the first 24 h 
of exposure to dexamethasone. However, in both 
studies the question has not been resolved whether 
the increase in concentration reflects more rapid 
synthesis (transcriptional or post transcriptional) 
or decreased .de~adation. In the case of the 
enkephalins, however, the ratio of Met to Leu 
enkephalin was preserved suggesting induction of 
the common precursor. 
In conclusion, the presence of a biologically ac- 
tive peptide (NPY) within several neuronal cell 
clones has been demonstrated. There is good 
reason to suppose that these cells will provide a 
useful system for the further ex~ination of the 
synthesis of NPY and related peptides from their 
precursor molecules. 
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